2nd Quarter 2007 Earnings Release Form 8-K
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported): May 10, 2007
AEOLUS
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or
other jurisdiction of incorporation)
0-50481 56-1953785
(Commission
File Number)
(IRS
Employer Identification No.)
23811
Inverness Place
Laguna
Niguel, California 92677
(Address
of Principal Executive Offices, Including Zip Code)
949-481-9825
(Registrant’s
Telephone Number, Including Area Code)
__________________
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
£ |
Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425) |
£ |
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12) |
£ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b)) |
£ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c)) |
Item
2.02 Results
of Operations and Financial Condition.
On
May
10, 2007, Aeolus Pharmaceuticals, Inc. issued an earnings release to announce
its earnings for the three months and six months ended March 31 2007.
The
earnings release is included in this report as Exhibit 99.1.
The
information in Exhibit 99.1 is being furnished and shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that Section. The
information in Exhibit 99.1 shall not be deemed incorporated by reference into
any registration statement or other document filed with the Securities and
Exchange Commission (the “SEC”), regardless of any general incorporation
language in such filing.
Item
9.01. Financial Statements and Exhibits.
Exhibit
#
|
|
Description
|
99.1
|
|
Press
release dated May 10, 2007
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this Report to be signed on its behalf by the undersigned hereunto
duly authorized.
AEOLUS
PHARMACEUTICALS, INC.
Date:
May
10, 2007
/s/
Michael P. McManus___________________
Michael
P. McManus
Chief
Financial Officer, Treasurer and Secretary